Clinical, anamnestic, molecular and genetic criteria for Lynch syndrome
نویسندگان
چکیده
منابع مشابه
Genetic Testing for FAP and Lynch Syndrome
The following Protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered s...
متن کاملMolDX: Genetic Testing for Lynch Syndrome LCD
AMA CPT / ADA CDT / AHA NUBC Copyright Statement CPT only copyright 2002-2017 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not rec...
متن کاملMolDX: Genetic Testing for Lynch Syndrome LCD
Contract Type Contract Number Jurisdiction State(s) Noridian Healthcare Solutions, LLC A and B MAC 02101 MAC A J F Alaska Noridian Healthcare Solutions, LLC A and B MAC 02102 MAC B J F Alaska Noridian Healthcare Solutions, LLC A and B MAC 02201 MAC A J F Idaho Noridian Healthcare Solutions, LLC A and B MAC 02202 MAC B J F Idaho Noridian Healthcare Solutions, LLC A and B MAC 02301 MAC A J F Oreg...
متن کاملEvaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.
Clinical criteria, primarily young age of cancer onset and family history of signature cancers, have been developed to identify individuals at elevated risk for Lynch syndrome with the goals of early identification and cancer prevention. In 2007, the Society of Gynecologic Oncology (SGO)-codified criteria for women presenting with gynecologic cancers. These criteria have not been validated in a...
متن کاملCurrent clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers
BACKGROUND Reported prevalence, penetrance and expression of deleterious mutations in the mismatch repair (MMR) genes, MLH1, MSH2, MSH6 and PMS2, may reflect differences in the clinical criteria used to select families for DNA testing. The authors have previously reported that clinical criteria are not sensitive enough to identify MMR mutation carriers among incident colorectal cancer cases. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advances in molecular oncology
سال: 2019
ISSN: 2413-3787,2313-805X
DOI: 10.17650/2313-805x-2019-6-4-38-46